Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCD-054 vs Avonex in RRMS
NCT02744222Phase 3Completed
- Sponsor
- BIOCAD
- Start
- Aug 2017
- Primary completion
- Nov 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of sampeginterferon beta-1a in relapsing-remitting multiple sclerosis (RRMS), sponsored by BIOCAD. Started Aug 2017; status: completed.
02
Drugs
sampeginterferon beta-1a
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT02744222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02744222.